Form 4: Sarepta Therapeutics Executive Louise Rodino-Klapac Reports Stock Transactions

Louise Rodino-Klapac, Head of R&D and CSO at Sarepta Therapeutics, reports acquisition and disposal of company stock and stock options.

Summary

• On March 1, 2024, Louise Rodino-Klapac, Head of R&D and CSO of Sarepta Therapeutics, reported transactions involving the company's stock.
• Rodino-Klapac disposed of 778 shares of common stock at $126.19 per share to cover tax obligations related to vesting restricted stock units.
• She also acquired 6,000 restricted stock units (RSUs), each representing the right to receive one share of common stock, which vest over four years.
• Additionally, Rodino-Klapac acquired 12,500 stock options with an exercise price of $128.67, vesting monthly from March 1, 2025, and expiring on March 1, 2034.
• Following these transactions, Rodino-Klapac beneficially owns 71,222 shares of common stock and 12,500 stock options.

Sentiment

Score: 6

Explanation: Neutral sentiment. The transactions are routine and expected as part of executive compensation. There's no indication of unusual activity or significant concern.

Positives

• The granting of RSUs and stock options to the Head of R&D and CSO could be seen as an incentive to drive company performance.
• Rodino-Klapac's continued holding of a significant number of shares (71,222) suggests confidence in the company's future.

Negatives

• The sale of shares to cover tax obligations, while common, could be interpreted as a need for liquidity.

Risks

• Executive stock transactions are always subject to scrutiny and can be interpreted in various ways by the market.
• The vesting schedule of the RSUs and stock options could influence the executive's short-term decision-making.

Industry Context

Executive stock transactions are a common occurrence in publicly traded companies and are routinely disclosed to the SEC. These transactions can provide insights into management's perspective on the company's value and future prospects. Investors often monitor these filings for signals, although they must be interpreted cautiously.

Comparison to Industry Standards

• Executive compensation packages, including stock options and RSUs, are standard practice in the biotechnology industry to attract and retain talent.
• Vesting schedules for stock options and RSUs, such as the four-year vesting period described in the document, are typical in the industry.
• Comparing the size of the RSU grant and stock option award to those of executives at comparable companies like BioMarin, Vertex, or Alnylam would provide a better understanding of the competitiveness of Sarepta's compensation practices.

Stakeholder Impact

• The transactions have a minor impact on shareholders, as they involve a relatively small number of shares compared to the company's total outstanding shares.
• Employees may be indirectly affected by the executive's actions, as they can influence the company's overall performance and stock price.

Key Dates